Urothelial carcinoma transmission via kidney transplantation

Ferreira, Gustavo Fernandes; Oliveira, Rosilene Aparecida de; Jorge, Lectícia Barbosa; Nahas, Willian; Saldanha, Luiz Balthazar; Ianhez, L E; Srougi, Miguel

doi:10.1093/ndt/gfp612

Cited by 16 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…46 Transmission of malignancy in an immunosuppressed recipient usually occurs when the tumor is undetected before the organ donation or it may be misdiagnosed as a benign condition such as cyst. 24 This incidence of tumor transmission may also have risen in recent years with the increased donor age. 8 In our review, more than half of the tumors were donor in origin-including both donor-derived and donor-transmitted malignancies.…”

Section: Discussionmentioning

confidence: 99%

“…The most common type of RCC was clear cell carcinoma (27%, n=9) 7,10,12-14,20,21,31 while the other types were: sarcomatoid (15%, n=5), 2,8 angiosarcoma (6%, n=2), 18 renal papillary tumor (6%, n=2), 28,31 anaplastic (6%, n=2), 25,29 chromophobe (3%, n=1), 16 cystic adenocarcinoma (3%, n=1), 31 anaplastic adenocarcinoma (3%, n=1), 29 giant and spindle cell carcinoma (3%, n=1), 15 and undifferentiated (6%, n=2). 17,22 The type of renal cell carcinoma was not mentioned in the rest (22%, n=7), 2,6,19,31 Other tumors (31%, n=15) comprised 31% of the cases which included: undifferentiated cancer (20%, n=3), 6 invasive urothelial carcinoma (7%, n=1), 24 papillary transitional cell carcinoma of bladder (7%, n=1). 31 Thirty-three percent of the tumors were subsequently found to be benign and the type of cancer was not mentioned in the rest (33%, n=5).…”

Section: Review Of Reported Casesmentioning

confidence: 99%

“…Explantation or excision was done in 90% of the nonmetastatic malignancies, while 84% of metastatic malignancies underwent explantation or excision. Chemotherapy, 6,7,12,24,28 radiotherapy, 13,18,29 or both 18 were also used in 9 cases. While 64% (n=7) of the 9 cases had metastasis, 7,12,13,17,18,24,32 18% (n=2), 29 had no metastasis, and the status of metastasis was not mentioned in the rest, (18%, n=2).…”

Section: Review Of Reported Casesmentioning

confidence: 99%

“…Actuarial 1-year and 5-year survival rates were 73.4% and 55.1% respectively. Out of eleven recipients, who died after transplant, 9 were due to malignancy-related causes, 6,8,11,15,17,18,24,26,29 while 2 were due to other causes. 2 The recipient in Llamas et al .…”

Section: Review Of Reported Casesmentioning

confidence: 99%

“…Metastasis of the cancer was the cause of death in four recipients, 15,17,18,29 while two recipients died due to intracerebral hemorrhage. 6,24 Death due to invasion of renal cell carcinoma (RCC) aggressively into adjacent tissue accounted for the death in the patient reported by Tunner et al . 11 Among the recipients from 7 donors who subsequently developed malignancy, 57% (n=4), 9,11,15,29 were dead within a year.…”

Section: Review Of Reported Casesmentioning

confidence: 99%

See 4 more Smart Citations

Renal Cancer in Recipients of Kidney Transplant

et al. 2016

View full text Add to dashboard Cite

The aim of our study is to determine characteristics and outcomes of kidney cancer in renal transplant recipients. MEDLINE® database was searched in June 2015 to identify cases of kidney cancer in renal transplant recipients. We include also a new case. Descriptive statistics were used for analysis. Forty-eight (48) recipients reported in 25 papers met the eligibility criteria. The median age was 47 years (range 9-66); 27% were females. Chronic glomerulonephritis, cystic kidney disease and hypertension were common indications for renal transplant. Among donors 24% were females and the median age was 52.5 years (17-73); 62% of kidney cancers were donor-derived. The median interval between transplant and cancer diagnosis was shorter for cancer of recipient versus donor origin (150 vs. 210 days). Clear cell carcinoma was diagnosed in 17%. 25% had metastasis at diagnosis. Kidney explantation or excision was done in 90% and 84% of cases with and without metastasis respectively. The median survival was 72 months. Actuarial 1-year and 5-year survival rates were 73.4% and 55.1% respectively. Among the recipients from 7 donors who subsequently developed malignancy, 57% were dead within a year. Kidney transplant recipients have a small risk of kidney cancer, which affects younger patients and occurs within a year of transplant, likely due to immunosuppression. Whether the use of older donors may increase the likelihood needs further investigation. The presence of metastasis, explantation or excision of affected kidney and development of cancer in donors predict outcomes. The results may guide patient education and informed decision-making.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Review Of Reported Casesmentioning

confidence: 99%

Section: Review Of Reported Casesmentioning

confidence: 99%

Section: Review Of Reported Casesmentioning

confidence: 99%

Section: Review Of Reported Casesmentioning

confidence: 99%

See 3 more Smart Citations

Renal Cancer in Recipients of Kidney Transplant

et al. 2016

View full text Add to dashboard Cite

show abstract

Organ Donor Risk Stratification in Italy

Peris

Bronzoni

Meli

et al. 2020

Textbook of Patient Safety and Clinical Risk Management

View full text Add to dashboard Cite

The permanent gap between organ demand and supply has prompted use of organs from extended criteria donors (ECD). These carry a higher risk of disease transmission, with regard to infections and malignancies. We present herein the donor risk stratification algorithm implemented in Italy since 2004 for identification management of donor-to-recipient risk of disease transmission. The principles underlying this algorithm are: (1) the risk of disease transmission must be assessed against the potential benefit for the transplant recipient (i.e., no donor can be excluded from evaluation and their organs might benefit potential candidates); (2) patients awaiting organ transplantation must be informed that the risk of disease transmission is small but finite (standard risk); and (3) risk evaluation is an ongoing process based on information collected longitudinally after transplantation. Regional and national transplant authorities are committed to regular updating of guidelines based on clinical data derived from clinicians and on evaluation of posttransplant graft and patient survival rates.

show abstract